SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LGND reported three and nine months ended September 30, 2026 results. The stock moved -0.5% on the print.
LGNDearnings

Earnings reactions, page 9

Ligand Pharmaceuticals Incorporated (LGND) FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Third-quarter 2026 royalty revenue was $70.3 million, compared with $46.6 million for the prior-year period.
  • Total revenues and income for the third quarter of 2026 were $78.7 million, compared with $115.5 million for the prior-year period.
  • GAAP net loss was $28.5 million, or $1.43 per share, for the third quarter of 2026.
  • Adjusted net income was $57.5 million, or $2.67 per diluted share, for the third quarter of 2026.
  • As of September 30, 2026, Ligand had cash, cash equivalents, and short-term investments of $447.4 million.

Guidance

  • Royalty revenue of $225 million to $250 million
  • Captisol sales of $35 million to $40 million
  • Contract revenue of $10 million to $20 million
  • Total revenue of $270 million to $310 million
  • Adjusted earnings per diluted share of approximately $9.50 to $9.75

Notes

Prior-year results included $53.1 million of income related to the Pelthos divestiture; results for the third quarter of 2026 included $39.5 million of pre-tax losses related to fair value changes of investments.

Price and volatility reaction

The stock moved -0.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.4 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release318.782026-10-28
Close after release317.332026-10-29
Realised move-0.5%close to close
30d ATM IV change-4.4 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →